Treatment of Experimental Nephrotic Syndrome with Artesunate
The present study was designed to test the therapeutic effect of a new antimalarial drug, artesunate in experimental model of nephrotic syndrome. To induce this experimental model, Adriamycin was given once by a single intravenous injection (7.5 mg/kg) through the tail vein. Six days after injection...
Gespeichert in:
| Veröffentlicht in: | International journal of toxicology 2007-07, Vol.26 (4), p.373-380 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 380 |
|---|---|
| container_issue | 4 |
| container_start_page | 373 |
| container_title | International journal of toxicology |
| container_volume | 26 |
| creator | Razavi, Alireza Nouri, Hamid R. Mehrabian, Farhad Mirshafiey, Abbas |
| description | The present study was designed to test the therapeutic effect of a new antimalarial drug, artesunate in experimental model of nephrotic syndrome. To induce this experimental model, Adriamycin was given once by a single intravenous injection (7.5 mg/kg) through the tail vein. Six days after injection of Adriamycin, therapeutic protocol was developed by intraperitoneally (IP) administration of 5 mg/kg artesunate (ARS). Total of IP injections were 14, of which 5 injections were made every day and 9 injections were carried out at regular 48-h intervals. Therapeutic protocol was terminated on day 28 and animals were killed on day 49. The results showed that treatment with ARS caused a significant reduction in the level of proteinuria, urine urea and urine sodium compared with nontreated controls. In addition, decrease in serum triglyceride and increase in the level of serum albumin was significant in treated group with ARS compared with nontreated controls. Moreover, treatment with ARS significantly reduced glomerular polymorphonuclear (PMN) and mononuclear cells infiltration, hypercellularity, karyorrhexis, wire loops, and hydropic change in capillary network within the renal cortex, as well as decreased hyalin casts. On the other hand, healthy controls receiving ARS showed a significant decrease in amounts of serum triglyceride, urine urea, and urine sodium and potassium compared with normal group. These data suggest that artesunate therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrotic syndrome; it may also be recommended as a lipid-lowering drug. |
| doi_str_mv | 10.1080/10915810701493293 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20809998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1080_10915810701493293</sage_id><sourcerecordid>20809998</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-aaad96e821f3d904e51c89e2d601c7bced67d1e60819ada1ca99651e352d9f2c3</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMotlZ_gBuZlbupuZmZTAJuSqkPKLqwgrshTe7YKfOoSQbtvze1BReCq_vgOwfOIeQS6BiooDdAJWQCaE4hlQmTyREZhh-LRZ6-Hf_sEAdADMiZc2tKKc8zOCUDyDkHxuSQ3C4sKt9g66OujGZfG7TV7lJ19ISble18paOXbWts12D0WflVNLEeXd8qj-fkpFS1w4vDHJHXu9li-hDPn-8fp5N5rFNgPlZKGclRMCgTI2mKGWghkRlOQedLjYbnBpBTAVIZBVpJyTPAJGNGlkwnI3K9993Y7qNH54umchrrWrXY9a5goQwppQgg7EFtO-cslsUmxFF2WwAtdpUVfyoLmquDeb9s0PwqDh0FYLwHnHrHYt31tg1h_3H8BkW6c8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20809998</pqid></control><display><type>article</type><title>Treatment of Experimental Nephrotic Syndrome with Artesunate</title><source>MEDLINE</source><source>SAGE Complete</source><source>Alma/SFX Local Collection</source><creator>Razavi, Alireza ; Nouri, Hamid R. ; Mehrabian, Farhad ; Mirshafiey, Abbas</creator><creatorcontrib>Razavi, Alireza ; Nouri, Hamid R. ; Mehrabian, Farhad ; Mirshafiey, Abbas</creatorcontrib><description>The present study was designed to test the therapeutic effect of a new antimalarial drug, artesunate in experimental model of nephrotic syndrome. To induce this experimental model, Adriamycin was given once by a single intravenous injection (7.5 mg/kg) through the tail vein. Six days after injection of Adriamycin, therapeutic protocol was developed by intraperitoneally (IP) administration of 5 mg/kg artesunate (ARS). Total of IP injections were 14, of which 5 injections were made every day and 9 injections were carried out at regular 48-h intervals. Therapeutic protocol was terminated on day 28 and animals were killed on day 49. The results showed that treatment with ARS caused a significant reduction in the level of proteinuria, urine urea and urine sodium compared with nontreated controls. In addition, decrease in serum triglyceride and increase in the level of serum albumin was significant in treated group with ARS compared with nontreated controls. Moreover, treatment with ARS significantly reduced glomerular polymorphonuclear (PMN) and mononuclear cells infiltration, hypercellularity, karyorrhexis, wire loops, and hydropic change in capillary network within the renal cortex, as well as decreased hyalin casts. On the other hand, healthy controls receiving ARS showed a significant decrease in amounts of serum triglyceride, urine urea, and urine sodium and potassium compared with normal group. These data suggest that artesunate therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrotic syndrome; it may also be recommended as a lipid-lowering drug.</description><identifier>ISSN: 1091-5818</identifier><identifier>EISSN: 1092-874X</identifier><identifier>DOI: 10.1080/10915810701493293</identifier><identifier>PMID: 17661229</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Animals ; Antimalarials - therapeutic use ; Artemisinins - therapeutic use ; Disease Models, Animal ; Doxorubicin - toxicity ; Drug Interactions ; Female ; Injections, Intraperitoneal ; Injections, Intravenous ; Kidney Glomerulus - drug effects ; Kidney Glomerulus - pathology ; Nephrotic Syndrome - chemically induced ; Nephrotic Syndrome - drug therapy ; Nephrotic Syndrome - metabolism ; Nephrotic Syndrome - pathology ; Proteinuria - chemically induced ; Proteinuria - drug therapy ; Proteinuria - metabolism ; Proteinuria - pathology ; Rats ; Rats, Sprague-Dawley ; Serum Albumin - analysis ; Sesquiterpenes - therapeutic use ; Sodium - urine ; Triglycerides - blood ; Urea - urine</subject><ispartof>International journal of toxicology, 2007-07, Vol.26 (4), p.373-380</ispartof><rights>Copyright © American College of Toxicology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-aaad96e821f3d904e51c89e2d601c7bced67d1e60819ada1ca99651e352d9f2c3</citedby><cites>FETCH-LOGICAL-c412t-aaad96e821f3d904e51c89e2d601c7bced67d1e60819ada1ca99651e352d9f2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1080/10915810701493293$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1080/10915810701493293$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17661229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Razavi, Alireza</creatorcontrib><creatorcontrib>Nouri, Hamid R.</creatorcontrib><creatorcontrib>Mehrabian, Farhad</creatorcontrib><creatorcontrib>Mirshafiey, Abbas</creatorcontrib><title>Treatment of Experimental Nephrotic Syndrome with Artesunate</title><title>International journal of toxicology</title><addtitle>SPIJT</addtitle><description>The present study was designed to test the therapeutic effect of a new antimalarial drug, artesunate in experimental model of nephrotic syndrome. To induce this experimental model, Adriamycin was given once by a single intravenous injection (7.5 mg/kg) through the tail vein. Six days after injection of Adriamycin, therapeutic protocol was developed by intraperitoneally (IP) administration of 5 mg/kg artesunate (ARS). Total of IP injections were 14, of which 5 injections were made every day and 9 injections were carried out at regular 48-h intervals. Therapeutic protocol was terminated on day 28 and animals were killed on day 49. The results showed that treatment with ARS caused a significant reduction in the level of proteinuria, urine urea and urine sodium compared with nontreated controls. In addition, decrease in serum triglyceride and increase in the level of serum albumin was significant in treated group with ARS compared with nontreated controls. Moreover, treatment with ARS significantly reduced glomerular polymorphonuclear (PMN) and mononuclear cells infiltration, hypercellularity, karyorrhexis, wire loops, and hydropic change in capillary network within the renal cortex, as well as decreased hyalin casts. On the other hand, healthy controls receiving ARS showed a significant decrease in amounts of serum triglyceride, urine urea, and urine sodium and potassium compared with normal group. These data suggest that artesunate therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrotic syndrome; it may also be recommended as a lipid-lowering drug.</description><subject>Animals</subject><subject>Antimalarials - therapeutic use</subject><subject>Artemisinins - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>Doxorubicin - toxicity</subject><subject>Drug Interactions</subject><subject>Female</subject><subject>Injections, Intraperitoneal</subject><subject>Injections, Intravenous</subject><subject>Kidney Glomerulus - drug effects</subject><subject>Kidney Glomerulus - pathology</subject><subject>Nephrotic Syndrome - chemically induced</subject><subject>Nephrotic Syndrome - drug therapy</subject><subject>Nephrotic Syndrome - metabolism</subject><subject>Nephrotic Syndrome - pathology</subject><subject>Proteinuria - chemically induced</subject><subject>Proteinuria - drug therapy</subject><subject>Proteinuria - metabolism</subject><subject>Proteinuria - pathology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Serum Albumin - analysis</subject><subject>Sesquiterpenes - therapeutic use</subject><subject>Sodium - urine</subject><subject>Triglycerides - blood</subject><subject>Urea - urine</subject><issn>1091-5818</issn><issn>1092-874X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEUhYMotlZ_gBuZlbupuZmZTAJuSqkPKLqwgrshTe7YKfOoSQbtvze1BReCq_vgOwfOIeQS6BiooDdAJWQCaE4hlQmTyREZhh-LRZ6-Hf_sEAdADMiZc2tKKc8zOCUDyDkHxuSQ3C4sKt9g66OujGZfG7TV7lJ19ISble18paOXbWts12D0WflVNLEeXd8qj-fkpFS1w4vDHJHXu9li-hDPn-8fp5N5rFNgPlZKGclRMCgTI2mKGWghkRlOQedLjYbnBpBTAVIZBVpJyTPAJGNGlkwnI3K9993Y7qNH54umchrrWrXY9a5goQwppQgg7EFtO-cslsUmxFF2WwAtdpUVfyoLmquDeb9s0PwqDh0FYLwHnHrHYt31tg1h_3H8BkW6c8w</recordid><startdate>200707</startdate><enddate>200707</enddate><creator>Razavi, Alireza</creator><creator>Nouri, Hamid R.</creator><creator>Mehrabian, Farhad</creator><creator>Mirshafiey, Abbas</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope></search><sort><creationdate>200707</creationdate><title>Treatment of Experimental Nephrotic Syndrome with Artesunate</title><author>Razavi, Alireza ; Nouri, Hamid R. ; Mehrabian, Farhad ; Mirshafiey, Abbas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-aaad96e821f3d904e51c89e2d601c7bced67d1e60819ada1ca99651e352d9f2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Antimalarials - therapeutic use</topic><topic>Artemisinins - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>Doxorubicin - toxicity</topic><topic>Drug Interactions</topic><topic>Female</topic><topic>Injections, Intraperitoneal</topic><topic>Injections, Intravenous</topic><topic>Kidney Glomerulus - drug effects</topic><topic>Kidney Glomerulus - pathology</topic><topic>Nephrotic Syndrome - chemically induced</topic><topic>Nephrotic Syndrome - drug therapy</topic><topic>Nephrotic Syndrome - metabolism</topic><topic>Nephrotic Syndrome - pathology</topic><topic>Proteinuria - chemically induced</topic><topic>Proteinuria - drug therapy</topic><topic>Proteinuria - metabolism</topic><topic>Proteinuria - pathology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Serum Albumin - analysis</topic><topic>Sesquiterpenes - therapeutic use</topic><topic>Sodium - urine</topic><topic>Triglycerides - blood</topic><topic>Urea - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Razavi, Alireza</creatorcontrib><creatorcontrib>Nouri, Hamid R.</creatorcontrib><creatorcontrib>Mehrabian, Farhad</creatorcontrib><creatorcontrib>Mirshafiey, Abbas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Razavi, Alireza</au><au>Nouri, Hamid R.</au><au>Mehrabian, Farhad</au><au>Mirshafiey, Abbas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Experimental Nephrotic Syndrome with Artesunate</atitle><jtitle>International journal of toxicology</jtitle><addtitle>SPIJT</addtitle><date>2007-07</date><risdate>2007</risdate><volume>26</volume><issue>4</issue><spage>373</spage><epage>380</epage><pages>373-380</pages><issn>1091-5818</issn><eissn>1092-874X</eissn><abstract>The present study was designed to test the therapeutic effect of a new antimalarial drug, artesunate in experimental model of nephrotic syndrome. To induce this experimental model, Adriamycin was given once by a single intravenous injection (7.5 mg/kg) through the tail vein. Six days after injection of Adriamycin, therapeutic protocol was developed by intraperitoneally (IP) administration of 5 mg/kg artesunate (ARS). Total of IP injections were 14, of which 5 injections were made every day and 9 injections were carried out at regular 48-h intervals. Therapeutic protocol was terminated on day 28 and animals were killed on day 49. The results showed that treatment with ARS caused a significant reduction in the level of proteinuria, urine urea and urine sodium compared with nontreated controls. In addition, decrease in serum triglyceride and increase in the level of serum albumin was significant in treated group with ARS compared with nontreated controls. Moreover, treatment with ARS significantly reduced glomerular polymorphonuclear (PMN) and mononuclear cells infiltration, hypercellularity, karyorrhexis, wire loops, and hydropic change in capillary network within the renal cortex, as well as decreased hyalin casts. On the other hand, healthy controls receiving ARS showed a significant decrease in amounts of serum triglyceride, urine urea, and urine sodium and potassium compared with normal group. These data suggest that artesunate therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrotic syndrome; it may also be recommended as a lipid-lowering drug.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>17661229</pmid><doi>10.1080/10915810701493293</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1091-5818 |
| ispartof | International journal of toxicology, 2007-07, Vol.26 (4), p.373-380 |
| issn | 1091-5818 1092-874X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20809998 |
| source | MEDLINE; SAGE Complete; Alma/SFX Local Collection |
| subjects | Animals Antimalarials - therapeutic use Artemisinins - therapeutic use Disease Models, Animal Doxorubicin - toxicity Drug Interactions Female Injections, Intraperitoneal Injections, Intravenous Kidney Glomerulus - drug effects Kidney Glomerulus - pathology Nephrotic Syndrome - chemically induced Nephrotic Syndrome - drug therapy Nephrotic Syndrome - metabolism Nephrotic Syndrome - pathology Proteinuria - chemically induced Proteinuria - drug therapy Proteinuria - metabolism Proteinuria - pathology Rats Rats, Sprague-Dawley Serum Albumin - analysis Sesquiterpenes - therapeutic use Sodium - urine Triglycerides - blood Urea - urine |
| title | Treatment of Experimental Nephrotic Syndrome with Artesunate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A03%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Experimental%20Nephrotic%20Syndrome%20with%20Artesunate&rft.jtitle=International%20journal%20of%20toxicology&rft.au=Razavi,%20Alireza&rft.date=2007-07&rft.volume=26&rft.issue=4&rft.spage=373&rft.epage=380&rft.pages=373-380&rft.issn=1091-5818&rft.eissn=1092-874X&rft_id=info:doi/10.1080/10915810701493293&rft_dat=%3Cproquest_cross%3E20809998%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20809998&rft_id=info:pmid/17661229&rft_sage_id=10.1080_10915810701493293&rfr_iscdi=true |